比较区域饱和活检、靶向活检与系统活检在前列腺特异性抗原4-20 ng/ml患者中的诊断表现:一项前瞻性、单中心、随机对照试验
本前瞻性单中心随机对照试验纳入434例活检初治、多参数磁共振成像(mpMRI)可疑病灶且前列腺特异性抗原(PSA)4-20 ng/ml的患者,比较区域饱和活检(RSB)、磁共振引导靶向活检(TB)与系统活检(SB)对临床显著前列腺癌(csPCa)的检出率;RSB检出率显著高于TB和SB,与TB+SB联合方案相当但所需活检针数更少。
要点
- RSB对csPCa检出率44.1%,显著高于TB的31.8%(p=0.01)和SB的34.1%(p=0.03)。
- RSB与TB+SB联合方案检出率44.1% vs 40.7%(p=0.3),无显著差异,但RSB所需活检针数更少。
- 全mount病理分析中RSB将97%(32/33)的前列腺癌灶识别为索引病灶,SB仅59.18%(29/49)。
核心结论
- 对于mpMRI可疑病灶且PSA 4-20 ng/ml的患者,RSB较磁共振引导TB和SB提高了临床显著前列腺癌的检出率,能准确识别索引病灶,并减少活检针数。
研究设计与样本
- 前瞻性、单中心、随机对照试验,纳入434例活检初治、mpMRI可疑病灶且PSA 4-20 ng/ml的患者,时间为2022年1月至2023年7月。
- RSB采用基于模板的九针疑似区域活检;比较RSB、TB和SB对csPCa的检出率,患者内比较采用McNemar检验,RSB与TB比较采用Fisher精确检验。
主要发现
- RSB对csPCa检出率44.1%,显著高于TB的31.8%(p=0.01)和SB的34.1%(p=0.03)。
- RSB与TB+SB联合方案对csPCa检出率44.1% vs 40.7%(p=0.3),无显著差异。
- RSB所需活检针数更少,且阳性针数比例更高以避免对整个前列腺取样(32.7% vs 18.3%,p<0.001)。
- 全mount组织病理学分析显示,RSB将97%(32/33)的前列腺癌灶识别为索引病灶,而SB为59.18%(29/49)。
- mpMRI低估组织学肿瘤平均直径的中位数为0.76 cm,凸显RSB操作中最佳活检区域的重要性。
关键数值与推荐
- RSB对csPCa检出率44.1% vs TB 31.8%(p=0.01),RSB显著更高。
- RSB对csPCa检出率44.1% vs SB 34.1%(p=0.03),RSB显著更高。
- RSB对csPCa检出率44.1% vs TB+SB联合方案40.7%(p=0.3),无显著差异。
- RSB阳性针数比例32.7% vs SB 18.3%(p<0.001),RSB更高。
- 全mount病理索引病灶识别率:RSB 97%(32/33)vs SB 59.18%(29/49)。
临床怎么用
- 对于mpMRI可疑病灶且PSA 4-20 ng/ml的活检初治患者,原文结论认为RSB较磁共振引导TB和SB提高了csPCa检出并减少活检针数。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the use of multiparametric magnetic resonance imaging (mpMRI)-guided targeted biopsy (TB) to identify suspicious prostate lesions, it may still miss clinically significant prostate cancer (csPCa) or result in false-negative findings. Recent evidence suggests that combining biopsies taken from within and around magnetic resonance imaging (MRI) lesions can improve the detection of csPCa. OBJECTIVE: This study aimed to compare the diagnostic performance of the regional saturation biopsy (RSB) method, involving template-based nine-core biopsies for suspected regions, with that of the MRI-directed TB and/or the systematic biopsy (SB) methods in biopsy-naïve patients with prostate-specific antigen (PSA) levels ranging from 4 to 20 ng/ml. DESIGN, SETTING, AND PARTICIPANTS: A prospective, single-center, randomized controlled trial included 434 biopsy-naïve patients with suspected lesions on mpMRI and PSA levels between 4 and 20 ng/ml (from January 2022 to July 2023). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The detection rates of csPCa for the RSB, TB, and SB methods were analyzed using the McNemar test for intrapatient comparisons. The Fisher's exact test was used for comparisons between RSB and TB. RESULTS AND LIMITATIONS: The RSB approach yielded a significantly higher detection rate of csPCa than both the TB approach (44.1% vs 31.8%, p = 0.01) and the SB approach (44.1% vs 34.1%, p = 0.03). The RSB approach exhibited a comparable detection rate of csPCa (44.1% vs. 40.7%, p = 0.3) to the combined approach (TB + SB), while requiring fewer biopsy cores and a higher positive core number to avoid sampling the entire prostate gland (32.7% vs 18.3%, p < 0.001). Upon conducting a whole-mount histopathological analysis, it was observed that the RSB approach successfully identified 97% (32 out of 33) of the prostate cancer foci as the index lesion, whereas only 59.18% (29 out of 49) were classified as index lesions using the SB approach. Furthermore, mpMRI underestimated the average diameter of histological tumor size by a median of 0.76 cm, highlighting the importance of an optimal biopsy area for the RSB procedure. CONCLUSIONS: For patients with suspected lesions on mpMRI and PSA levels between 4 and 20 ng/ml, the RSB approach has shown improved detection of clinically significant prostate cancer, accurately identifying index lesions, and minimizing biopsy cores compared with the MRI-directed TB and SB approaches. PATIENT SUMMARY: For patients with suspected lesions on multiparametric magnetic resonance imaging and prostate-specific antigen levels between 4 and 20 ng/ml, the regional saturation biopsy method provides enhanced detection of clinically significant prostate cancer, as well as precise identification of index lesions, surpassing both magnetic resonance imaging-directed targeted biopsy and the systematic biopsy method.
引用
- Jiang X, Chen M, Tian J, et al. Comparison of Regional Saturation Biopsy, Targeted Biopsy, and Systematic Biopsy in Patients with Prostate-specific Antigen Levels of 4-20 ng/ml: A Prospective, Single-center, Randomized Controlled Trial. Eur Urol Oncol. 2023. PMID: 38158249. doi:10.1016/j.euo.2023.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。